When it comes to clinical trials, time is money.
And a delay in a trial can mean a drop in a drug's net value, lost ground to competitors, or an increased risk of failure — or it can signal more bad news to come.
Our latest STAT Report is a practical guide to evaluating clinical trial delays. In Clinical Trial Delays: What they mean and why you should care, we help you unpack why clinical trials delay matter, the potential impacts, and how to separate the signal from the noise. Whether you're a seasoned expert or a biotech newbie, this report will help you be more confident, methodical, and thoughtful the next time you're assessing a clinical trial delay.
And, for the first time ever, with the purchase of this report you will receive one month of access to STAT Trials Pulse, Applied XL's AI-powered platform that automates clinical trials intelligence, saving you time and surfacing early risk indicators.
This report is written by the clinical trial expert Frank David. David is the founder and managing director of Pharmagellan, a biopharma consultancy that focuses on R&D strategy David has written two popular drug industry handbooks on biotech forecasting and clinical trials.
GET THE REPORT
About STAT Reports
STAT Reports help business executives, researchers, consultants, and analysts navigate the ever-changing life sciences industry. Each report provides deep analysis of a particular issue in health care. Pick and purchase the reports that are most relevant to you.
LEARN MORE
Other topics include:
No comments